Metformin

Women's health (London, England) · 2025

Researchers observed that metformin can help manage polycystic ovary syndrome (PCOS) by improving insulin resistance, which may enhance ovulation and increase pregnancy rates. They found that combining metformin with clomifene citrate is more effective for women resistant to clomifene alone, while continuing metformin during early pregnancy may reduce miscarriage rates.

• Metformin improves hormonal balance and increases ovulation in women with PCOS.
• Combining metformin with clomifene citrate is more effective than either treatment alone.
• Continuing metformin during early pregnancy may lower miscarriage rates.

Phytomedicine : international journal of phytotherapy and phytopharmacology · 2024

Researchers observed that the Zhimu-Huangbai herb-pair significantly improved liver health in mice with non-alcoholic fatty liver disease (NAFLD) by reducing fat buildup. This effect was linked to the herb-pair's ability to regulate certain proteins involved in lipid metabolism and stress responses in liver cells.

• Zhimu-Huangbai reduced liver fat accumulation in mice on a high-fat diet.
• The herb-pair inhibited the production of a protein called SREBP-1c, which is involved in fat synthesis.
• The treatment helped relieve stress in liver cells, contributing to its protective effects against NAFLD.

Metabolism: clinical and experimental · 2022

Researchers observed that metformin, originally developed for type 2 diabetes, may have potential benefits for various diseases, including cancer and neurodegenerative conditions. They found that while its primary effects are related to blood sugar control, metformin may also improve overall health and reduce disease risk through other mechanisms.

• Metformin is primarily effective for type 2 diabetes but shows promise for other diseases.
• It may help reduce cancer incidence and protect against neurodegenerative diseases.
• The drug's benefits may extend beyond blood sugar control, enhancing overall health.

Cell metabolism · 2020

Researchers observed that metformin, a drug commonly used for diabetes, may help slow down the aging process by targeting various biological mechanisms associated with aging. This includes improving how cells communicate, protecting against cellular damage, and delaying the aging of stem cells, making it a promising candidate for future studies on aging.

• Metformin improves nutrient sensing and enhances cell communication.
• It protects against cellular damage and delays stem cell aging.
• Metformin shows potential as a treatment to target aging in humans.

Diabetologia · 2017

Researchers observed that metformin, originally derived from a traditional herbal medicine, has become the preferred treatment for type 2 diabetes due to its ability to lower blood sugar without causing weight gain or hypoglycemia. Its long-term cardiovascular benefits were recognized in the late 1990s, solidifying its role as a first-line therapy.

• Metformin was rediscovered in the 1940s and first used for diabetes in 1957.
• It gained popularity after being shown to have cardiovascular benefits in the UK Prospective Diabetes Study.
• Metformin is now the most prescribed glucose-lowering medication worldwide.

Nature medicine · 2017

Researchers found that metformin, a common medication for type 2 diabetes, significantly changes the gut microbiome of patients. These changes may help improve blood sugar control, as shown in experiments with mice receiving fecal samples from metformin-treated individuals. The study highlights the important role of gut bacteria in the drug's effectiveness.

• Metformin alters the gut microbiome in individuals with type 2 diabetes.
• These microbiome changes are linked to improved blood sugar control.
• Experiments with mice suggest that the altered gut bacteria contribute to metformin's effects.

Diabetes, obesity & metabolism · 2017

Researchers found that many patients with type 2 diabetes struggle to tolerate metformin due to gastrointestinal issues like diarrhea and nausea. They observed that while adjusting the dosage and exploring different formulations can help, some patients may still need alternative treatments if they cannot tolerate metformin at all.

• Gastrointestinal side effects are common with metformin, affecting patient adherence.
• Starting with a low dose and increasing slowly may reduce side effects.
• Alternative therapies should be considered if metformin is not tolerated.

Diabetes care · 2016

Researchers observed that combining empagliflozin and metformin significantly lowered blood sugar levels in patients with type 2 diabetes compared to using either medication alone. They also found that this combination led to greater weight loss without increasing the risk of low blood sugar episodes. Overall, the treatment was well tolerated by participants.

• Combination therapy reduced blood sugar levels more effectively than monotherapy.
• Patients experienced greater weight loss with the combination treatment.
• The treatment was well tolerated with no increased risk of hypoglycemia.

Diabetologia · 2016

Researchers observed that metformin, a common medication for type 2 diabetes, has significant effects on the gastrointestinal tract, influencing glucose uptake and gut bacteria. They found that a new delayed-release version of metformin may improve blood sugar control with fewer side effects, suggesting that the gut plays a crucial role in how well metformin works for individuals.

• Metformin affects glucose uptake and lactate production in the gut.
• A new delayed-release formulation shows similar effectiveness with fewer side effects.
• The gut's role is important in how individuals respond to metformin.

Drugs · 2005

Researchers found that combining rosiglitazone and metformin is more effective at controlling blood sugar levels in people with type 2 diabetes than using metformin alone. This combination therapy was well tolerated by patients, with only a small percentage experiencing mild hypoglycemia.

• Rosiglitazone increases insulin sensitivity, while metformin reduces glucose production in the liver.
• The fixed-dose combination of rosiglitazone and metformin significantly lowered HbA1c and fasting plasma glucose levels compared to metformin alone.
• The combination therapy had a similar safety profile to metformin monotherapy.